Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Phase 3

Completed

Brief Summary: The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.

Recruitment & Eligibility

Inclusion Criteria

Histologically or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.
Measurable disease based on RECIST v1.1.
Be considered ineligible to receive cisplatin-based combination therapy, based on protocol-defined criteria.
Have provided tissue for PD-L1 analysis from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
Have received no prior systemic chemotherapy for advanced/unresectable (inoperable) or metastatic urothelial cancer.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 14 days prior to randomization.
Adequate organ function per protocol-defined criteria.

Exclusion Criteria

Disease that is suitable for local therapy administered with curative intent.
Known additional malignancy that is progressing or has required active treatment within the past 3 years.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging, clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
Active autoimmune disease that has required systemic treatment in past 2 years.
Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
Known history of or is positive for active hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or has active hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.
History of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption.
History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.
Use of protocol-defined prior/concomitant therapy.

Arm && Interventions

Group	Intervention	Description
Pembrolizumab 200 mg + epacadostat 100 mg BID	Epacadostat	Pembrolizumab + epacadostat
Pembrolizumab 200 mg + epacadostat 100 mg BID	Pembrolizumab	Pembrolizumab + epacadostat
Pembrolizumab 200 mg + placebo BID	Placebo	Pembrolizumab + placebo
Pembrolizumab 200 mg + placebo BID	Pembrolizumab	Pembrolizumab + placebo

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo	Week 9	ORR was defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 by investigator determination. Responses are based on Investigator assessments per RECIST 1.1 without confirmation using all scans up to the cutoff date.

Secondary Outcome Measures

Name	Time	Method
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo as Measured by Number of Participants Experiencing Adverse Events (AEs)	Up to approximately 25 months	AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo as Measured by Number of Participants Discontinuing Study Treatment Due to AE	Up to approximately 25 months	AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Locations (143): Arizona Oncology Associates PC- HOPE
🇺🇸
Tucson, Arizona, United States
University of California Irvine Medical Center
🇺🇸
Orange, California, United States
Yale Cancer Center
🇺🇸
New Haven, Connecticut, United States
Woodlands Medical Specialists, PA
🇺🇸
Pensacola, Florida, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Quincy Medical Group
🇺🇸
Quincy, Illinois, United States
Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
GU Research Network-Urology Cancer Center
🇺🇸
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
🇺🇸
Las Vegas, Nevada, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
🇺🇸
New York, New York, United States
Scroll for more (133 remaining)
Arizona Oncology Associates PC- HOPE
🇺🇸Tucson, Arizona, United States